SELLAS Life Sciences Group, Inc. (SLS), late-stage clinical biopharmaceutical company focused on development of cancer therapies, announced it has entered into an exclusive license agreement with GenFleet Therapeutics (Shanghai), Inc. that grants rights to SELLAS for the development and commercialization of GFH009, a highly selective small molecule cyclin-dependent kinase 9 inhibitor, across all therapeutic and diagnostic uses worldwide outside of China.
GFH009, currently in Phase 1 clinical trials in the United States and China, is a highly selective next-generation CDK9 inhibitor. CDK9 activity has been shown to negatively correlate with overall survival in a number of cancer types, including hematologic cancers, such as acute myeloid leukemia ("AML") and lymphomas, as well as solid cancers, such as osteosarcoma, pediatric soft tissue sarcomas, and melanoma, and endometrial, lung, prostate, breast and ovarian cancer.
Under the financial terms of the agreement, SELLAS will pay to GenFleet an initial payment of $10 million as an upfront license and technology transfer fee. The company will also pay development and regulatory milestone payments for up to three indications totaling up to $48 million and milestone payments totaling up to $92 million in upon the achievement of certain sales thresholds of GFH009 in the United States and rest of the world.
SELLAS will also pay GenFleet tiered royalties based on a percentage of annual net sales of GFH009 ranging from the low to high single digits.
SLS closed Thursday's trading at $6.68, down $0.18 or 2.62%, on the Nasdaq. The stock further dropped $1.63 or 24.40% in the after-hours trading.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.